The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This is expected to drive a substantial increase in the number of trials seeking to enroll children. Parents and caregivers are likely to have many questions when considering whether to enroll a child in a clinical trial, and children, perhaps particularly adolescents, will also have their own lists of questions, so adequate time must be allowed for these questions to be asked and answered.
CAR T-Cell Therapies – The Holy Grail of Therapeutic Innovation in Hemato-Oncology and its Challenges from a CRO Perspective
Kids with Cancer: A Survivor Shares Her Story
Recruiting Solid Tumor Patients in a Complex ADME Trial
PRA's PPS facility in Budapest (PPS-Hungary) was contracted to run an open-label, non-randomized, Phase I study to characterize the mass balance and…